Could You Be Missing ADMA Biologics Stock’s Upside?

Here is why we think ADMA Biologics (ADMA) stock deserves consideration as a value stock. It is currently trading nearly 36% below its 1 year high, and also trading at a PS multiple which is below the average for the last 3 years. However, it has reasonable fundamentals for its level of valuation.

• Reasonable Revenue Growth: 43.6% LTM and 63.8% last 3 year average.
• Cash Generative: Nearly 13.8% free cash flow margin and 32.8% operating margin LTM.
• No Major Margin Shocks: ADMA Biologics has avoided any margin collapse in the last 12 months.
• Modest Valuation: Despite encouraging fundamentals, ADMA stock trades at a PE multiple of 18.0
• Opportunity vs S&P: Compared to S&P, you get lower valuation, higher revenue growth, and better LTM fcf and operating margins

As a quick background, ADMA Biologics provides development, manufacturing, and marketing of specialty plasma-derived biologics, including intravenous immune globulin products for primary immunodeficiency and treatments for acute Hepatitis B exposure.

ADMA stock may swing. A balanced allocation doesn’t. Empirical Asset Management blends strategy and discipline to smooth out market noise.

*LTM: Last Twelve Months

But do these numbers tell the full story? Read Buy or Sell ADMA Stock to see if ADMA Biologics still has an edge that holds up under the hood.

Stocks Like These Can Outperform. Here Is Data

Below are statistics for stocks with same selection strategy applied between 12/31/2016 and 6/30/2025.

• Average 6-month and 12-month forward returns of 12.7% and 25.8% respectively
• Win rate (percentage of picks returning positive) of > 70% for both 6-month and 12-month periods
• Not over dependent on market crashes. During non-crash periods as well, this strategy has 12-month average return of nearly 20% with 67% win rate.

But Consider The Risk

That said, ADMA isn’t immune to steep drops. It fell about 68% during the 2018 correction, nearly 67% in the Covid pandemic sell-off, and around 63% during the inflation shock. These aren’t minor pullbacks. Even with strong fundamentals, the stock shows it can take a big hit when markets turn sour. Risk remains, no matter the positives.

But the risk is not limited to major market crashes. Stocks fall even when markets are good – think events like earnings, business updates, outlook changes. Read ADMA Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.